PURPOSE: Earlier, we showed in acute myeloid leukemia (AML) patients that the microbiota changes dramatically during anticancer treatment, coinciding with gastrointestinal mucositis: The commensal anaerobic populations reduce in favor of potential pathogens. Therefore, interventions targeting the microbiota during mucositis might be interesting but can better be tested in animals than in vulnerable mucositis patients. Here, we aimed to study the potential microbial changes during methotrexate (MTX)-induced gastrointestinal mucositis in a well-established rat model and to study whether this model can be used for future microbial intervention studies. METHODS: After injection with MTX or saline (day 0), rats were sacrificed between days 2 and 11. Plasma citrulline level, jejunal histology, and the number and diversity of intestinal bacteria in feces (using fluorescence in situ hybridization (FISH)) were determined. RESULTS: Mucositis was most severe on day 4 when food intake, plasma citrulline, and villus length were the lowest, compared with controls (P < 0.0125). At the same time, MTX-treated rats showed an overall decrease (705-fold) in most bacteria (using a universal probe), compared with controls (P < 0.125). Reduced bacterial presence was related with the presence of diarrhea and a reduced villus length (rho = 0.38, P < 0.05). At day 4, there was an absolute and relative decrease of anaerobes (13-fold and -58 %, respectively) and streptococci (296-fold and -1 %, respectively) but a relative increase of Bacteroides (+49 %), compared with controls (P < 0.125). CONCLUSIONS: In the mucositis rat model, we found substantial decreases in the number and diversity of microbiota, resembling earlier findings in humans. The model therefore seems well suited to study the effects of different microbial interventions on mucositis, prior to performing human studies.
PURPOSE: Earlier, we showed in acute myeloid leukemia (AML) patients that the microbiota changes dramatically during anticancer treatment, coinciding with gastrointestinal mucositis: The commensal anaerobic populations reduce in favor of potential pathogens. Therefore, interventions targeting the microbiota during mucositis might be interesting but can better be tested in animals than in vulnerable mucositispatients. Here, we aimed to study the potential microbial changes during methotrexate (MTX)-induced gastrointestinal mucositis in a well-established rat model and to study whether this model can be used for future microbial intervention studies. METHODS: After injection with MTX or saline (day 0), rats were sacrificed between days 2 and 11. Plasma citrulline level, jejunal histology, and the number and diversity of intestinal bacteria in feces (using fluorescence in situ hybridization (FISH)) were determined. RESULTS:Mucositis was most severe on day 4 when food intake, plasma citrulline, and villus length were the lowest, compared with controls (P < 0.0125). At the same time, MTX-treated rats showed an overall decrease (705-fold) in most bacteria (using a universal probe), compared with controls (P < 0.125). Reduced bacterial presence was related with the presence of diarrhea and a reduced villus length (rho = 0.38, P < 0.05). At day 4, there was an absolute and relative decrease of anaerobes (13-fold and -58 %, respectively) and streptococci (296-fold and -1 %, respectively) but a relative increase of Bacteroides (+49 %), compared with controls (P < 0.125). CONCLUSIONS: In the mucositisrat model, we found substantial decreases in the number and diversity of microbiota, resembling earlier findings in humans. The model therefore seems well suited to study the effects of different microbial interventions on mucositis, prior to performing human studies.
Authors: Hermie J M Harmsen; Gerwin C Raangs; Tao He; John E Degener; Gjalt W Welling Journal: Appl Environ Microbiol Date: 2002-06 Impact factor: 4.792
Authors: Parameth Thiennimitr; Sebastian E Winter; Maria G Winter; Mariana N Xavier; Vladimir Tolstikov; Douglas L Huseby; Torsten Sterzenbach; Renée M Tsolis; John R Roth; Andreas J Bäumler Journal: Proc Natl Acad Sci U S A Date: 2011-10-03 Impact factor: 11.205
Authors: Nita H Salzman; Hendrik de Jong; Yvonne Paterson; Hermie J M Harmsen; Gjalt W Welling; Nicolaas A Bos Journal: Microbiology Date: 2002-11 Impact factor: 2.777
Authors: Michel J van Vliet; Wim J E Tissing; Catharina A J Dun; Nico E L Meessen; Willem A Kamps; Eveline S J M de Bont; Hermie J M Harmsen Journal: Clin Infect Dis Date: 2009-07-15 Impact factor: 9.079
Authors: Alan W Walker; Sylvia H Duncan; Hermie J M Harmsen; Grietje Holtrop; Gjalt W Welling; Harry J Flint Journal: Environ Microbiol Date: 2008-08-15 Impact factor: 5.491
Authors: James L Alexander; Ian D Wilson; Julian Teare; Julian R Marchesi; Jeremy K Nicholson; James M Kinross Journal: Nat Rev Gastroenterol Hepatol Date: 2017-03-08 Impact factor: 46.802
Authors: Ronay Thomas; Wendy S W Wong; Reem Saadon; Thierry Vilboux; John Deeken; John Niederhuber; Suchitra K Hourigan; Elizabeth Yang Journal: Pediatr Hematol Oncol Date: 2020-05-19 Impact factor: 1.969
Authors: J Bowen; N Al-Dasooqi; P Bossi; H Wardill; Y Van Sebille; A Al-Azri; E Bateman; M E Correa; J Raber-Durlacher; A Kandwal; B Mayo; R G Nair; A Stringer; K Ten Bohmer; D Thorpe; R V Lalla; S Sonis; K Cheng; S Elad Journal: Support Care Cancer Date: 2019-07-08 Impact factor: 3.603
Authors: Zélia Menezes-Garcia; Raquel Duque Do Nascimento Arifa; Leonardo Acúrcio; Camila Bernardo Brito; Júlia Oliveira Gouvea; Renata Lacerda Lima; Rafael Wesley Bastos; Ana Carolina Fialho Dias; Luana Pereira Antunes Dourado; Leandro F S Bastos; Celso Martins Queiroz-Júnior; Carlos Eduardo Dias Igídio; Rafael De Oliviera Bezerra; Leda Q Vieira; Jacques R Nicoli; Mauro Martins Teixeira; Caio T Fagundes; Daniele G Souza Journal: Gut Microbes Date: 2020-06-23
Authors: Armin Rashidi; Ryan Shanley; Shernan G Holtan; Margaret L MacMillan; Bruce R Blazar; Alexander Khoruts; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2018-07-07 Impact factor: 5.742